Atypical hemolytic-uremic syndrome after COVID-19 vaccine: A case report

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorGonçalves Dias Square-
Autor(es): dc.contributorFaculty of Medicine of University Center of Maranhão-
Autor(es): dc.contributorJerônimo de Albuquerque Avenue-
Autor(es): dc.creatorCampos, Marcos Adriano Garcia-
Autor(es): dc.creatorAtaídes, Rômullo José Costa-
Autor(es): dc.creatorFerreira, Maxwell Cabral-
Autor(es): dc.creatorAlves, Adriano Soares-
Autor(es): dc.creatorSilva, Gyl Eanes Barros-
Data de aceite: dc.date.accessioned2025-08-21T19:03:32Z-
Data de disponibilização: dc.date.available2025-08-21T19:03:32Z-
Data de envio: dc.date.issued2025-04-29-
Data de envio: dc.date.issued2024-07-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1002/iid3.1270-
Fonte completa do material: dc.identifierhttps://hdl.handle.net/11449/300365-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/300365-
Descrição: dc.descriptionBackground: The emergence of new SARS-CoV-2 variants and the global COVID-19 pandemic spurred urgent vaccine development. While common vaccine side effects are well-documented, rare adverse events necessitate post-marketing surveillance. Recent research linked messenger RNA vaccines to thrombotic microangiopathy (TMA), a group of syndromes characterized by microvascular hemolytic anemia and thrombocytopenia. This report describes a new-onset atypical hemolytic-uremic syndrome (aHUS) occurring after COVID-19 vaccination and complements recent literature. Case Presentation: A previously healthy 25-year-old woman developed malaise, nausea, edema, and renal dysfunction 60 days postvaccination. Laboratory findings confirmed TMA diagnosis. Genetic testing for complement system mutations was negative. Kidney biopsy supported the diagnosis, and the patient required hemodialysis. Conclusion: This case illustrates the rare occurrence of aHUS following COVID-19 vaccination, with unique characteristics compared to previous reports. Despite the critical role of vaccination in pandemic control, emerging adverse events, such as vaccine-related TMA, must be recognized and investigated. Additional clinical trials are imperative to comprehend the clinical features and pathophysiological mechanisms underlying TMA associated with COVID-19 vaccination.-
Descrição: dc.descriptionClinical Hospital of Botucatu Medical School of São Paulo State University Mário Rubens Guimarães Montenegro Avenue-
Descrição: dc.descriptionFaculty of Medicine of Federal University of Maranhão Gonçalves Dias Square-
Descrição: dc.descriptionFaculty of Medicine of University Center of Maranhão-
Descrição: dc.descriptionDr Carlos Macieira Hospital Jerônimo de Albuquerque Avenue-
Descrição: dc.descriptionClinical Hospital of Botucatu Medical School of São Paulo State University Mário Rubens Guimarães Montenegro Avenue-
Idioma: dc.languageen-
Relação: dc.relationImmunity, Inflammation and Disease-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectatypical hemolytic-uremic syndrome-
Palavras-chave: dc.subjectcase report-
Palavras-chave: dc.subjectpost-COVID-19-
Palavras-chave: dc.subjectthrombotic microangiopathy-
Título: dc.titleAtypical hemolytic-uremic syndrome after COVID-19 vaccine: A case report-
Tipo de arquivo: dc.typetexto-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.